- Home
- »
- Biotechnology
- »
-
Recombinant Proteins Manufacturing Services Market Report, 2033GVR Report cover
Recombinant Proteins Manufacturing Services Market (2026 - 2033)
Size, Share & Trends Analysis Report By Service (Pre-clinical & Clinical, Commercial Production), By Host Cell (Mammalian Cells, Bacterial Cells, Insect Cells, Yeast & Fungi), By End Use, By Region, And Segment Forecasts
Market Size, 2025
$5.6BMarket Estimate, 2026
$6.6BMarket Forecast, 2033
$20.1BCAGR, 2026–2033
17.2%Recombinant Proteins Manufacturing Services Market Summary
The global recombinant proteins manufacturing services market size was valued at USD 5.6 billion in 2025 and is projected to grow from USD 6.6 billion in 2026 to USD 20.1 billion in 2033, at a CAGR of 17.2% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 35.0% in 2025. The increasing adoption of outsourcing for recombinant protein manufacturing, the growing preference for biologics & biosimilars, the high prevalence of chronic disorders, and increasing applications of proteins are expected to boost market expansion.
Key Market Trends & Insights
- By service: The commercial production segment held the largest market share of around 60.0% in 2025.
- By host cell: The mammalian segment held the largest market share of over 55.0% in 2025.
- By end use: The pharmaceutical & biotechnology companies segment held the largest market share of over 75.0% in 2025.
Regional Insights
- Largest regional market: North America (35.0% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026 - 2033)
Market Size & Forecast
- Market size in 2025: USD 5.6 Billion
- Estimated market size in 2026: USD 6.6 Billion
- Projected market size by 2033: USD 20.1 Billion
- CAGR (2026-2033): 17.2%
Prism AI by Grand View Research Free to tryAsk a question about the recombinant proteins manufacturing services marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
According to the American Cancer Society, in the U.S., there were an estimated 618,120 cancer deaths and 2.04 million newly diagnosed cancer cases in 2025. As recombinant proteins are widely used in cancer research and diagnosis, an increase in the cancer burden is projected to boost demand for proteins, driving market growth. Moreover, the high burden of cancer creates a need for advanced therapeutics, leading to increased adoption of outsourcing services for the production of advanced therapies.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
Protein production is a cost-intensive process that requires specialized facilities and large-scale production capabilities. Several challenges related to regulatory compliance and adherence to manufacturing standards can further complicate the production of recombinant protein-based products. As a result, in recent years, the trend toward outsourcing recombinant protein production to leverage CMO expertise and capabilities has increased. Furthermore, certain specialized and repetitive activities, such as fill/finish, analytical testing/bioassays, and toxicology testing, are outsourced to a greater extent in the biopharmaceutical industry.
Recombinant proteins are used in the development of innovative therapeutics for a variety of chronic conditions, including cancer and other rare disorders. The creation of recombinant pharmaceutical proteins in heterologous systems, introducing complementary RNA (cRNA) and DNA (cDNA) from one species into cells of another species to produce the desired protein, has seen increased demand in recent years. Furthermore, there is an increasing need for advanced protein production platforms since many recombinant protein applications require complex proteins & glycoproteins that are challenging for biotech companies to manufacture.
In addition, with the ongoing advancements in recombinant technology, novel applications of proteins for developing personalized medicine, cell & gene therapies, and bioengineering products are projected to increase. For instance, in January 2025, ProBioGen expanded its GMP protein manufacturing capabilities by adding a new 1,000 L production line at its Berlin facility to support increasing demand for recombinant protein and biologics manufacturing services. These factors are expected to significantly increase demand for recombinant proteins, driving growth in the manufacturing services market.
Analyst Perspective
The market is experiencing steady growth, driven by increasing demand for biologics, rising investment in biopharmaceutical research, and growing interest in targeted therapeutics. Pharmaceutical and biotechnology companies are increasingly using recombinant protein manufacturing services to accelerate drug development, improve production efficiency, and ensure high product quality. The expanding pipeline of monoclonal antibodies, vaccines, therapeutic proteins, and cell and gene therapies is further supporting market growth. As demand for scalable, cost-effective, and regulatory-compliant manufacturing solutions continues to rise, companies that focus on process innovation, capacity expansion, and service diversification will be well-positioned to capitalize on long-term growth opportunities.
Service Insights
The commercial production services segment held the largest market share, at around 60.0%, in 2025. The development of recombinant DNA technology, cell culture methods, and protein expression systems, and the growing accessibility of high-yield expression systems such as mammalian cell lines, yeast, and bacteria, which can boost production productivity & efficiency, are among the factors driving the commercial production services market.
The pre-clinical & clinical services segment is expected to witness the fastest CAGR over the forecast period. The segment is expected to witness lucrative growth over the forecast period due to an increasing focus on precision medicine and targeted therapies, as well as the growing need to outsource clinical trial design, data collection, and analysis.
Host Cell Insights
The mammalian segment accounted for the largest market share, at around 55.0%, in 2025. For manufacturing complex recombinant proteins that need significant folding, subunit assembly, and/or posttranslational modifications, mammalian cells are appropriate host cells. These features contribute to understanding the preference for mammalian cells in the biotech and pharmaceutical sectors for manufacturing diagnostic and therapeutic proteins.
The yeast & fungi segment is estimated to witness the fastest CAGR over the forecast period. Yeasts are now used in several healthcare fields, including the generation of therapeutic recombinant proteins and their traditional application in fermentation. Yeast cells are particularly appealing as hosts for biopharmaceutical synthesis as they are generally considered safe organisms. This is expected to drive market expansion throughout the forecast period.
End Use Insights
The pharmaceutical & biotechnology companies segment held the largest market share of over 75.0% in 2025. Numerous major and small biotechnology businesses are driving innovation in service and manufacturing capabilities, creating commercial potential for market expansion. For instance, in April 2025, FUJIFILM Biotechnologies and Regeneron Pharmaceuticals entered into a 10-year manufacturing agreement valued at more than USD 3 billion to support large-scale biologics production at FUJIFILM’s Holly Springs, North Carolina, facility. The agreement is expected to strengthen global capacity for biologics and recombinant protein manufacturing while addressing the growing demand for outsourced production services.
The academic & research institutes industry segment is estimated to witness the fastest CAGR from 2026 to 2033. As recombinant technology advances, novel uses of recombinant proteins that enable the development of customized medicines, cell and gene therapies, and bioengineering products are expected to grow rapidly. For example, the development of gene-editing technologies such as CRISPR-Cas9 enabled precise modification of recombinant proteins to develop novel therapies. These factors are projected to significantly increase demand for recombinant proteins in academic and research institutes, thereby driving growth in the manufacturing services industry.
Regional Insights
North America held the largest market share, over 35.0%, of the recombinant protein manufacturing services market in 2025. This can be attributed to increased research spending, the availability of well-established healthcare infrastructure, and the existence of several industry participants. These factors are expected to increase the demand for recombinant protein manufacturing services. According to the CDC, nearly 129 million people in the U.S. were living with at least one major chronic disease in 2025. The increasing prevalence of chronic conditions is driving demand for recombinant protein therapeutics, including monoclonal antibodies, hormones, enzymes, and growth factors, thereby supporting the expansion of recombinant protein manufacturing services worldwide. Such a high disease rate is expected to increase demand for recombinant proteins, fueling market expansion throughout the forecast period.
To learn more about this report,Download Free Sample Report
Asia Pacific Recombinant Proteins Manufacturing Services Market Trends
The recombinant proteins manufacturing services market in the Asia Pacific is expected to experience the fastest CAGR from 2026 to 2033 due to improved healthcare infrastructure, improving economic conditions, increased government efforts to raise awareness, and favorable regulatory policies that will boost the adoption of recombinant manufacturing services. Furthermore, the region's increased need for high-quality healthcare has a favorable impact on the industry.
Key Recombinant Proteins Manufacturing Services Company Insights
The recombinant proteins manufacturing services industry features a range of global, regional, and local players, making it a competitive market. The world’s leading companies are using partnerships, collaborations, acquisitions, mergers, and agreements as strategies to withstand the intense competition and increase their market share. The continuous demand for recombinant protein manufacturing services by multiple applications has created numerous market opportunities for major players to capitalize on.
Key Recombinant Proteins Manufacturing Services Companies
The following key companies have been profiled for this study on the recombinant proteins manufacturing services market.
-
Lonza
-
Boehringer Ingelheim International GmbH
-
FUJIFILM Diosynth Biotechnologies
-
Merck KGaA
-
Bruker (InVivo BioTech Services GmbH)
-
Sino Biological, Inc.
-
GenScript
-
Kaneka Corporation (Kaneka Eurogentec S.A)
-
Polyplus Transfection (Xpress Biologics)
-
Boster Biological Technology
-
Trenzyme GmbH
Recent Developments
-
In February 2026, Dyadic Applied BioSolutions and Proliant Health & Biologicals announced the commercial launch of AlbuFree DX, a recombinant human albumin product manufactured using Dyadic’s proprietary expression technology. The launch marked a significant commercialization milestone in recombinant protein manufacturing and expanded the availability of animal-free recombinant proteins for life science, biopharmaceutical, and diagnostic applications.
-
In April 2025, FUJIFILM Biotechnologies signed a 10-year U.S. manufacturing agreement valued at more than USD 3 billion with Regeneron Pharmaceuticals to provide large-scale biologics manufacturing services from its Holly Springs, North Carolina, facility. The agreement expanded long-term biologics production capacity and reflected growing demand for outsourced recombinant protein and biologics manufacturing services.
-
In January 2025, ProBioGen expanded its protein manufacturing capabilities by commissioning an additional 1,000L GMP production line at its Berlin facility. The investment increased production capacity for recombinant proteins and biologics while strengthening the company’s end-to-end contract development and manufacturing (CDMO) service offerings.
Recombinant Proteins Manufacturing Services Market Report Scope
Report Attribute
Details
Market size in 2025
USD 5.6 billion
Estimated market size in 2026
USD 6.6 billion
Projected market size by 2033
USD 20.1 billion
Growth rate
CAGR of 17.2% from 2026 to 2033
Actual data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD billion, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Service type, host cell, end use, region
Regional Scope
North America; Europe; Asia Pacific; Latin America; MEA
Country Scope
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; Switzerland; Netherlands; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Lonza; Boehringer Ingelheim International GmbH; FUJIFILM Diosynth Biotechnologies; Merck KGaA; Bruker (InVivo BioTech Services GmbH); Sino Biological, Inc.; GenScript, Kaneka Corporation (Kaneka Eurogentec S.A); Polyplus Transfection (Xpress Biologics); Boster Biological Technology; Trenzyme GmbH
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail of customized purchase options to meet your exact research needs. Explore purchase options
Global Recombinant Proteins Manufacturing Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global recombinant proteins manufacturing services market report based on service, host cell, end user, and region:
To learn more about this report,Download Free Sample Report
-
Service Type Outlook (Revenue, USD Million, 2021 - 2033)
-
Pre-clinical & Clinical Services
-
Commercial Production Services
-
-
Host Cell Outlook (Revenue, USD Million, 2021 - 2033)
-
Mammalian Cells
-
Bacterial Cells
-
Insect Cells
-
Yeast & Fungi
-
Others
-
-
End-user Outlook (Revenue, USD Million, 2021 - 2033)
-
Pharmaceutical & Biotechnology Companies
-
Academic & Research Institutes
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
Switzerland
-
Netherlands
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Frequently Asked Questions About This Report
The global recombinant proteins manufacturing services market is expected to grow at a CAGR of 17.2% from 2026 to 2033, reaching USD 20.1 billion.
Key players include Lonza; Boehringer Ingelheim International GmbH; FUJIFILM Diosynth Biotechnologies; Merck KGaA; Bruker (InVivo BioTech Services GmbH); Sino Biological, Inc.; GenScript, Kaneka Corporation (Kaneka Eurogentec S.A); Polyplus Transfection (Xpress Biologics); Boster Biological Technology; Trenzyme GmbH
North America dominated with a 35.0% revenue share in 2025.
Commercial production dominated the recombinant proteins manufacturing services market with a share of around 60.0% in 2025.
The global recombinant proteins manufacturing services market size was valued at USD 5.6 billion in 2025 and is estimated at USD 6.6 billion for 2026.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.